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Abstract
Currently, all European countries offer some form of breast cancer screening. Neverthe-
less, disparities exist in the status of implementation, attendance and the extent of
opportunistic screening. As a result, breast cancer screening has not yet reached its full
potential. We examined how many breast cancer deaths could be prevented if all Euro-
pean countries would biennially screen all women aged 50 to 69 for breast cancer. We
calculated the number of breast cancer deaths already prevented due to screening as
well as the number of breast cancer deaths which could be additionally prevented if the
total examination coverage (organised plus opportunistic) would reach 100%. The calcu-
lations are based on total examination coverage in women aged 50 to 69, the annual
number of breast cancer deaths for women aged 50 to 74 and the maximal possible
mortality reduction from breast cancer, assuming similar effectiveness of organised and
opportunistic screening. The total examination coverage ranged from 49% (East), 62%
(West), 64% (North) to 69% (South). Yearly 21 680 breast cancer deaths have already
been prevented due to mammography screening. If all countries would reach 100%
examination coverage, 12 434 additional breast cancer deaths could be prevented
annually, with the biggest potential in Eastern Europe. With maximum coverage, 23% of
their breast cancer deaths could be additionally prevented, while in Western Europe it
could be 21%, in Southern Europe 15% and in Northern Europe 9%. Our study illus-
trates that by further optimising screening coverage, the number of breast cancer
deaths in Europe can be lowered substantially.
K E YWORD S
breast cancer mortality, breast cancer mortality reduction, breast cancer screening, screening
coverage, screening guidelines
1 | INTRODUCTION
Breast cancer is a major public health problem in Europe. It is by far
the most frequently diagnosed neoplasm in European women and is
Abbreviations: BC, Breast cancer; CI, Confidence Interval; GDG, Guidelines Development
Group; HR, Hazard Ratio; OR, odds ratio; RCT, randomised controlled trial.
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responsible for nearly one third of all new cancer cases among women
in 31 European countries in 2018.1 Breast cancer is also the leading
cause of death in European women.1,2
Randomised trials and several observational studies have demon-
strated that systematic screening of eligible women through quality-
assured population-based programmes for breast cancer reduces mor-
tality from this disease.3-15
Based on this evidence, in 2003 the European Commission's Ini-
tiative on Breast cancer Guidelines Development Group (GDG) publi-
shed their first guidelines for organised mammography screening
programmes for early detection of breast cancer in asymptomatic
women with a strong recommendation to inviting women ages 50 to
69, every 2 years.16,17 The guidelines and recommendations have
been updated and expanded regularly ever since based on updated
evidence on efficacy or diagnostics, resulting in extending the recom-
mendations to triennial or biennial screening the age-groups 45 to 49
and 70 to 74 in the context of an organised screening programme.17
At present, breast cancer screening programmes are well
established in most European countries and all have some form of
screening for breast cancer. Nevertheless, disparities exist in terms of
the status of implementation, the extent to which screening
programmes are organised, the invitation coverage, the coexistence with
opportunistic screening activity and the attendance to screening.18
In order to know to which extent the European recommendations
have been adopted, reports on the implementation have been publi-
shed in 2007 and 2017.3,18 It was shown here as well as in other stud-
ies that the coverage of (organised) screening is of key importance in
order to tap the full public health potential in terms of reduction in
mortality from breast cancer.19,20
However, in most European countries, opportunistic and
organised screening coexist. Thus, to expect mortality reductions only
from population-based screening programmes would probably lead to
an underestimation of the total effectiveness of screening.
The primary aim of our study was to investigate what the effect
would be of an increased or even complete breast cancer screening
coverage on breast cancer mortality for each European country and if
this effect differs between the four European regions. Therefore, we
estimate how many breast cancer deaths have already been
prevented due to screening and how many deaths could additionally
be prevented if countries would screen all women in the age-group
50 to 69 years every 2 years for breast cancer with a hypothetical
100% coverage of screening in the advised target age groups. The
secondary aim was to provide an overview of screening practice and
the amount of organised as well as opportunistic screening in Europe.
2 | METHODS
2.1 | Data
2.1.1 | Data providers
As part of the EU-TOPIA project (TOwards imProved screening for
breast, cervical and colorectal cancer In All of Europe), we collected
data (see indicators listed in this section) of a recent year from over
36 data providers from 31 countries (see list of collaborators). They
were either European screening organisers, researchers and/or
policymakers. The data providers were contacted to collect any miss-
ing data, to correct any apparent inconsistencies and to approve on
the use of it. For only a few countries (Greece, Portugal and Romania),
data were completely missing despite best efforts of the authors to
involve potential data providers. By utilising other data sources like
published reports3 or online databases (eg, the Cancer Mortality Data-
base of the WHO21 or ECIS—European Cancer Information System22),
we filled these data gaps.
While our focus was clearly on national data, those were not
available for a few countries. In Belgium, Spain, Sweden, Switzerland
and the United Kingdom, health care delivery is organised at regional
level with effectively independent screening programmes. Therefore,
the data for the Belgian regions as well as the data for Scotland,
Northern Ireland, England and Wales are presented separately in our
study, while the data providers from Spain, Sweden and Switzerland
could provide national estimates.
2.1.2 | Indicators
Examination coverage of organised screening
Based on the IARC Handbook of Cancer Prevention (2015),23 we
defined organised screening as screening programmes organised at
the national or regional level, with an explicit policy, including an
active invitation of the entire target population and monitoring of can-
cer occurrence in the target population. For our study, the examina-
tion coverage of organised screening was specified as the proportion
(%) of the target population (here: 50- to 69-year-old women)
screened in the chosen report year after invitation. For countries
without a population-based programme, the proportion is zero.
Examination coverage of opportunistic screening
Opportunistic or nonorganised screening refers to all other breast
cancer screening activity where individual invitations are not sent to
the women in the eligible population or when women undergo a
mammography outside or additionally to the (existing) screening pro-
gramme.3,23 Mammograms for symptomatic women are not counted
What's new?
Breast cancer is the leading cause of death among European
women. Although screening for breast cancer is available in
all European countries, not all eligible women aged 50-69
get screened. Here, the authors calculated how many deaths
could be prevented if screening coverage reached 100%,
considering both organized and opportunistic screening.
Already, screening prevents 21 680 deaths per year, and if
all countries reached full examination coverage, an additional
12 434 deaths per year could be prevented across Europe.
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as opportunistic screening. Generally, opportunistic screening is not
monitored and is thus difficult to quantify. We asked the data pro-
viders to estimate opportunistic breast cancer screening by utilising
insurance data, survey results or by providing their expert opinion. If
that was not possible, we applied the mean examination coverage of
opportunistic screening of the European region.
Total examination coverage
We based our calculations on the total examination coverage as the
sum of both organised and opportunistic examination coverage. For
countries without an organised breast cancer screening programme
and no estimate of opportunistic screening, we applied the region-
specific average of the total examination coverage.
Breast cancer deaths
We included the absolute number of breast cancer deaths in women
aged 50 to 74 years in the report year for each country or region
within a country. In addition to the recommended screening ages
range 50 to 69, we included breast cancer deaths for five additional
years in ages 70 to 74 to account for death occurring after the last
screening round.
Mortality reduction
The maximal possible mortality reduction is taken from a recently
published systematic review on breast cancer mortality reduction due
to screening.7 In this publication, the authors identified those studies
among 61 included studies that provided best evidence for breast
cancer mortality reduction due to screening for each European region,
based on observed data.
The identified studies (Table 1) represent point estimates for
breast cancer mortality reduction due to breast cancer screening for
each European region. These point estimates were 33% in Finland
(North), 50% in Italy (South) and 58% in the Netherlands (West). We
assume those reductions to be the same across all screened age
groups. No studies from Eastern Europe met the initial inclusion
criteria and subsequently evidence for mortality reduction due to
breast cancer screening was lacking. Consequently, for these coun-
tries, we applied the point estimate from Southern Europe as it is the
medium value and because these two regions may seem fairly compa-
rable in terms of the extent of screening coverage and the role of
opportunistic screening.
2.2 | Calculations
We calculated for each country the number of breast cancer deaths
which have already been prevented due to screening as well as the
number of breast cancer deaths which could be additionally prevented
if the total examination coverage (organised plus opportunistic) would
reach 100%, assuming similar effectiveness of organised and opportu-
nistic screening. We made four more assumptions to base our calcula-
tions on: first, that the underlying breast cancer mortality between
current screening attenders and nonattenders is similar. Second, the
maximal effect of breast cancer mortality reduction due to breast can-
cer screening differs across European regions, but is assumed to be
the same in each of the region's countries, respectively. Third, the
effects of breast cancer related therapy on the improvement of breast
cancer specific mortality are implicitly accounted for in the level of
reported breast cancer mortality and possible levels of breast cancer
mortality reduction. They are also assumed to be the same in each
region. And fourth, that the relationship between examination cover-
age and breast cancer mortality reduction is a linear one. Through lin-
ear interpolation of the point estimates from the best evidence
studies for each European region, we were able to assign a potential
breast cancer mortality reduction to any level of total screening cover-
age (calculation examples for each region are in Figure 1).
For example, based on the point estimates of breast cancer mor-
tality reduction due to screening from the best evidence in each
region (Table 1), the number of breast cancer deaths that were already
prevented in a North European country would be calculated as
0.0033*total examination coverage*annual number of breast cancer
deaths of women aged 50 to 74. For a South and East European coun-
try, it would be 0.005*total examination coverage*annual number of
breast cancer deaths of women aged 50 to 74 and for a West Euro-
pean country 0.0058*total examination coverage*annual number of
breast cancer deaths of women aged 50 to 74.
In contrast, the breast cancer deaths that could be additionally
prevented if the screening coverage would increase to 100% is based
on the number of breast cancer deaths in the absence of screening (ie,
the observed number of breast cancer deaths plus the breast cancer
deaths that have already been prevented). In a North European coun-
try, this number would be calculated as (−0.0033*total examination
coverage + 0.33)*annual number of breast cancer deaths of women
aged 50 to 74 in the absence of screening. For a South and East
TABLE 1 Overview of point estimates of breast cancer mortality reduction due to breast cancer screening from best evidence studies, per
European region
Study Region Country Study type Target age
Effect sizes for breast cancer
mortalitya, (95% CI)
Heinavaara et al9 North Finland Case-control 50-69 HR = 0.67 (0.49-0.90)b
Puliti et al24 South Italy Case-control 50-74 OR = 0.50 (0.42-0.60)b
Paap et al12 West Netherlands Case-control 50-75 OR = 0.42 (0.33-0.53)b
Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio.
aAttenders/nonattenders.
bEstimates corrected for self-selection bias.
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European country, it would be (−0.005*total examination coverage
+ 0.5)*annual number of breast cancer deaths of women aged 50 to
74 in the absence of screening and for a West European country
(−0.0058*total examination coverage + 0.58)*annual number of
breast cancer deaths of women aged 50 to 74 in the absence of
screening (Figure 1).
Despite differences in target age range and frequency, for our
study all calculations were based on the hypothetical situation of a
uniform policy of screening women biennially between the ages 50
and 69. The observed coverage rates were adjusted accordingly.
2.3 | Sensitivity analyses
Because of uncertainties around some assumptions made, the follow-
ing sensitivity analyses were performed.
A sensitivity analysis was performed in which potential gains were
calculated up to a maximal coverage of 84%, which is the highest
screening coverage found in a European country (ie, Denmark).
In addition, sensitivity analyses were performed in which the effec-
tiveness of opportunistic screening was 10%, 20%, and 30% lower than
organised screening. In these analyses, the percentages that could be
gained to reach an examination coverage of 100% were distributed
over organised and opportunistic screening to the same distribution as
was already present in the specific country [eg, if present screening
coverage was 40% organised and 20% opportunistic (ratio 2:1), the
additional coverage was 27% organised and 13% opportunistic (2:1)].
To assess the impact of the regional point estimates on the maxi-
mal possible breast cancer mortality reduction on the regional results
of our study, we performed a sensitivity analysis where we varied the
point estimates across all European countries, that is, we applied a
33% (North), a 50% (South) and a 58% (West) breast cancer mortality
reduction due to screening irrespective of the location of the country.
3 | RESULTS
3.1 | Screening practice and examination coverage
Most European countries adopted the target age range for breast can-
cer screening as recommended by the European Commission for
which there is a strong recommendation (50-69). Only a few countries
adopted a different age range and either invite women younger than
50 or they invite women beyond the age of 69, while a few stop
Region breast cancer deaths already prevented Additionally preventable breast cancer deaths 
North y = 0.0033 * total examination coverage y = –0.0033 * total examination coverage + 0.33 
South y = 0.005 * total examination coverage y = –0.005 * total examination coverage + 0.5 
West y = 0.0058 * total examination coverage y = –0.0058 * total examination coverage + 0.58 
East  y = 0.005 * total examination coverage y = –0.005 * total examination coverage + 0.5 
By means of this graph, the number of already prevented breast cancer deaths and additionally preventable breast cancer deaths can be derived for any possible country.  
The blue line (squares) represents the interpolated trend of the already prevented breast cancer deaths when the maximal possible breast cancer mortality reduction is 33% (Northern
Europe). In a hypothetical Northern European country, the total examination coverage is 60% and 3000 annual breast cancer deaths occur. These deaths need to be multiplied with 
the value on the y-axis resulting from the respective value on the x-axis (total examination coverage). Or alternatively. 0.0033*60=0.198 and 0.198*3,000=594. Thus, 594 women did 
not die of breast cancer due to current screening activity.  
To calculate the corresponding number of breast cancer deaths that could be additionally prevented if the examination coverage would increase to 100%, one needs to calculate the 
number of breast cancer deaths in the absence of screening first (ie, the observed number of breast cancer deaths plus the breast cancer deaths that have already been prevented, 
thus 3,000 plus 594). Based on the total examination coverage, following the red line (circles), one can take the respective factor from the y-axis that these 3594 deaths need to be 
multiplied with (or alternatively, y = -0.0033 * total examination coverage + 0.33). Hence,  we calculated the factor on the y-axis to be 0.132 (-0.0033*60+0.33) and therefore 474 





F IGURE 1 (Potential) breast cancer mortality reduction, per total examination coverage (example region North) [Color figure can be viewed
at wileyonlinelibrary.com]
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Examination coverage 50-69 (%)a
Organised Opportunistic Total
North
Denmark 2014 521 81.1 3.0 84.1
Estoniab 2016 121 37.4 8.0 45.4
Finland 2014 390 78.9 3.9 82.8
Iceland 2015 25 58.7 2.0 60.7
Latvia 2016 247 26.7 8.1 34.8
Lithuania 2016 265 44.2 5.0 49.2
Norway 2016 347 72.3 5.0 77.3
Swedenc 2016 605 76.5 1.0 77.5
Total North 2521 59.5 4.5 64.0
West
Austriad 2014 658 25.0 20.0 45.0
Wallonia (B) 2015 386 7.0 45.0 52.0
Brussels (B) 2015 69 11.6 42.0 53.6
Vlaanderen (B) 2015 736 51.0 18.2 69.2
Francec 2015 5043 51.6 13.5 65.1
Germany 2015 7575 51.2 5.0 56.2
Irelande 2015 335 53.3 3.9 57.2
Luxembourg 2013 29 56.0 5.7 61.7
Netherlandsc 2015 1628 75.8 5.0 80.8
Switzerland 2015 616 14.5 10.5 25.0
Scotland (United Kingdom)f,g 2015 444 62.1 0 62.1
N. Ireland (United Kingdom)f,g 2016 133 81.4 0 81.4
Wales (United Kingdom)f,g 2016 264 76.6 0 76.6
England (United Kingdom)f,g 4115 4115 75.4 0 75.4
Total West 21 972 49.0 12.1 61.5
East
Bulgaria 2015 711 — 49.0 49.0h
Croatia 2015 533 37.5 12.0 49.5
Czech Republicd 2016 823 57.6 3.0 60.6
Hungaryi 2015 1197 22.5 19.5 42.0
Poland 2016 3421 38.7 19.9 58.6
Romaniaj 2016 1867 — 49.0 49.0h
Slovakia 2017 542 — 30.0 30.0
Slovenia 2015 177 40.1 13.0 53.1
Total East 9271 39.3 16.2 49.0
South
Cyprus 2017 58 35.1 32.4k 63.1
Greecej 2016 824 — 68.9 h
Italy 2013 3900 42.3 19 61.3
Maltag 2016 40 52.9 19.5 72.4
Portugalc,j 2013 762 33.8 32.4k 66.2
Spain 2016 2644 62 19.5 81.5
Total South 8228 45.2 32.4 68.9
aThe examination coverage of organised/opportunistic screening was specified as the proportion (%) of the target population (here: 50- to 69-year-old
women) screened in the index year after invitation.
bScreening ages 50 to 62.
cScreening ages 50 to 74.
dScreening ages 45 to 69.
eScreening ages 50 to 64.
fNo opportunistic screening activity due to The Ionising Radiation (Medical Exposure) Regulations 2017.
gThree-years screening interval.
hTotal screening is average or the region.
iScreening ages 45 to 64.
jData from ECIS,22 Globocan21 and the second screening report.3
kOpportunistic screening is average of the region.
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inviting women at the age of 62 and 64, respectively. The screening
interval was 2 years in all countries except for Malta and the United
Kingdom where three yearly screening was practiced (Table 2).
The examination coverage of organised breast cancer screening
was highest in Northern Europe and lowest in Eastern Europe (an
average of 59% compared to 39%; Table 2). In contrast, the examina-
tion coverage of opportunistic screening was lowest in Northern
Europe and highest in Southern Europe (5% compared to 32%). The
total examination coverage ranged from 49% in Eastern Europe, 62%
in Western Europe, 64% in Northern Europe to 69% in Southern
Europe. With 84% and 25%, Denmark and Switzerland had the
highest and the lowest total examination coverage, respectively.
3.2 | Prevented breast cancer deaths
Based on the collected data, 42 051 women die of breast cancer in
Europe every year. Due to the existence of breast cancer screening,
21 680 breast cancer deaths have already been prevented annually.
Consequently, with no breast cancer screening activities, 63 731
women would have died of the cancer. Thus, 34% of breast cancer spe-
cific deaths have been prevented due to mammography screening
across Europe. We calculated that 12 434 breast cancer deaths could
additionally be prevented annually if breast cancer screening coverage
would be extended to 100%. The regional results are presented in
Figure 2 where Western Europe sticks out due to its population size as
well as the biggest regional point estimate of breast cancer mortality
reduction. In Western Europe, 22 031 women died of breast cancer in
the reported year (red column). Due to the average total examination
coverage of 61.5%, 13 147 breast cancer deaths were already averted.
Hence, in the absence of screening, 35 178 women would have died
annually of breast cancer (red striped column). If screening coverage
would increase to 100%, only 14 742 breast cancer deaths would occur
(gray striped column) as 7298 additional breast cancer deaths could be
averted annually. The respective numbers for all European countries
and regions are presented in Table 3. Figure 3 presents the relative
effect of a 100% total examination coverage for each country, that is,
showing the share of breast cancer deaths that could additionally be
prevented when countries would screen all women 50 to 69 years of
age every 2 years. Most countries could potentially avert additional
20% to 29% of their breast cancer deaths. In contrast, all Nordic coun-
tries have consistently high coverage rates through their organised
programmes and less additional breast cancer deaths could potentially
be prevented when screening would be extended to 100%.
Northern Europe: Denmark, Estonia, Finland Iceland, Latvia, Lithuania, Norway and Sweden. 
Western Europe: Austria, Belgium, France, Germany, Ireland, Luxembourg, The Netherlands, United Kingdom and Switzerland. 
Eastern Europe: Bulgaria, Czech Republic, Croatia, Hungary, Poland, Romania, Slovakia and Slovenia. 
Southern Europe: Cyprus, Gibraltar, Greece, Italy, Malta, Portugal and Spain 
3305
35 178










































Breast cancer deaths in the absence of screening
Observed breast cancer deaths with current screening examination coverage
Breast cancer deaths if screening examination coverage would increase to 100%
F IGURE 2 Annual number of observed and preventable breast cancer deaths, ages 50 to 74, per European region [Color figure can be viewed
at wileyonlinelibrary.com]
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3.3 | Sensitivity analyses
As shown in Table 3, assuming a maximal coverage of 84% instead of
100% led to a significant drop in prevented breast cancer deaths
(6975 averted deaths compared to 12 438). This cut is predominantly
explained by countries who already have a comparably high screening
coverage and lose the additional benefit of increasing up to 100% (eg,
the Netherlands, Spain or Denmark).
Assuming that opportunistic screening is 10% less effective as
organised screening led to a 5% reduction of the additionally prevent-
able breast cancer deaths. A 20% and 30% lowered effectiveness led
to a 10% and 14% reduction, respectively. The effect was biggest in
countries with a high percentage of opportunistic screening (eg, Wal-
lonia/Belgium). Applying the Western European point estimate for
mortality reduction across all of Europe, breast cancer deaths already
prevented increased by 14% and breast cancer deaths that can addi-
tionally be prevented increased by 13%. This analysis has the biggest
impact for Northern Europe (plus 223%), where the point estimate
was the smallest in the base analysis. When the estimates from North-
ern and Southern Europe were applied, the number of breast cancer
deaths prevented decreased by 49% and 10%, while the additionally
preventable breast cancer deaths decreased by 48% and 10%, respec-
tively, compared to the base calculation.
4 | DISCUSSION
Our study illustrates how breast cancer screening in Europe already
has a substantial impact by preventing nearly 21 700 breast cancer
deaths per year. In addition, through further optimising screening cov-
erage, the number of breast cancer deaths of European women could
be further reduced significantly. The effect would be particularly nota-
ble in Eastern and Western Europe. Thus, rolling-out a breast cancer
screening programme with complete coverage across the country is
F IGURE 3 Percentage of breast cancer deaths that could be additionally prevented if examination coverage would increase to 100%, per
European country*. *Belgium is depicted as one country whereas in the calculation three highly autonomous regions Flanders, Wallonia and
Brussels are included. These regions have very disparate screening programs for breast cancer (see Table 2) resulting in very different effects of
an increased total examination coverage (Table 3). Only 8 of the 26 Swiss cantons have organised breast cancer screening programmes which
causes substantial variation in the distribution of organised vs opportunistic screening across regions. On a national level, total examination
coverage was only 25% in 2015 (14% organised and 11% opportunistic) according to the national expert. Thus, a national examination coverage
of 100% would further reduce breast cancer deaths by 44% [Color figure can be viewed at wileyonlinelibrary.com]
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particularly favourable for Swiss women as it would further reduce
breast cancer deaths by 44%. In contrast, all Nordic countries have
consistently high coverage rates through their organised programmes
(between 72% and 81%) plus a very low coverage of opportunistic
screening for breast cancer (between 1% and 5%). When the total
examination coverage for women aged 50 to 69 is already as high as
84%, not many additional breast cancer deaths could potentially be
prevented if screening was extended to 100%.
Screening provides both harms and benefits, and therefore it is
important to ensure a good balance between the two. Information on
the balances of benefits and harms is needed to demonstrate that a
chosen screening policy and programme with all its components and
protocols is appropriate for any given country. In this article, however,
we focus solely on the primary aim of (organised) breast screening
which is to reduce mortality from breast cancer through early
detection.16,20
The calculations for this present analysis are based on the
assumption that opportunistic and organised breast cancer screening
can lead to the same level of cancer specific mortality reduction.
However, past studies resulted in slightly conflictive results. For
example, a study in Denmark found that the sensitivity was twice as
high for organised screening, while the specificity of organised and
opportunistic screening was found to be similar.25 Hofvind et al com-
pared opportunistic breast cancer screening in Vermont (Unit-
ed States) with organised breast cancer screening in Norway.26 Both
screening systems detected cancer at about the same rate and at the
same prognostic stage. A study from Switzerland found that there
was little difference in stage distribution and detection rates between
cantons with only opportunistic screening and cantons with both
organised and opportunistic screening,27 indicating that both are simi-
larly effective. It was noted, however, that the quality of opportunistic
screening in Switzerland probably benefitted from the training of
radiographers, a higher reading volume of radiologists and the techni-
cal and quality-controlled procedures of the organised programme.
In summary, the main differences between organised and oppor-
tunistic screening can be seen in attendance,28 equity,28 and cost-
effectiveness29 which are all (much) better in organised screening.
With regards to quality aspects, opportunistic screening might be
quite similar to that of organised screening. Moreover, since opportu-
nistic screening takes place next to organised screening in most coun-
tries (Bulgaria, Romania, Slovakia and Greece being the exception), it
can profit from advantages of the organised system. Consequently,
we are confident that by conflating opportunistic and organised
screening for calculations and argumentations, we can increase the
relevance of this article.
The European guidelines for quality assurance in breast cancer
screening and diagnosis consider participation rates above 70% as
acceptable and above 75% as desirable.30 In line with those guide-
lines, we do not actually propagate a screening coverage of 100% as
this probably conflicts with informed choice.31 However, by basing
our calculations on a hypothetical goal of a screening coverage of
100% of eligible women, we assessed the maximum potential of
breast cancer screening for each country.
Our study focuses on screening women ages 50 to 69 as this is
currently the practice in most European countries. Despite some
exceptions (Table 2), women aged 70 to 74 are usually not eligible for
mammography screening because there was insufficient evidence that
screening would reduce mortality for women in this age group. Previ-
ous randomised controlled trials (RCTs) and observational studies on
breast cancer screening have not generally included women aged
70 years and over. In their newest (conditional) screening recommen-
dations, however, the European Commission Initiative on Breast Can-
cer suggests that average-risk and asymptomatic women between 45
and 49, as well as between 70 and 74 years old, have mammography
screening for breast cancer.
Several further considerations inform the interpretation of our
study. There is an ongoing debate as to which study design is the gold
standard for estimating the true effect of screening on cancer-specific
mortality.23,32,33 For our study, we considered that high-quality case-
control studies7 provide the most informative data. RCTs were con-
ducted more than 20 years ago when adherence to screening was less
and the quality of screening programmes and breast cancer care were
less advanced than today. In contrast, observational studies of screen-
ing are known to be prone to bias as there is no unselected
unscreened group. Women who do not participate in screening might
have a higher a priori risk of breast cancer mortality. If that was so,
our assumption of a proportional relationship between screening cov-
erage and reduction in breast cancer mortality would not hold. There-
fore, it was of particular importance to base our analysis on estimates
of mortality reduction that were not influenced by self-selection bias.
The regional point estimates from individual studies on mortality
reduction due to breast cancer screening, which our calculations are
based on, differ quite significantly. These differences indicate differ-
ences in evaluation designs, in target ages, in ages of follow-up of
breast cancer incidence or mortality, in duration of follow-up since
first invitation, in comparison groups and in assessment methods of
self-selection bias.7,9,12,24 Therefore, the region-specific point esti-
mates are not directly comparable with each other and they should
not be used as a ‘quality indicator’ for organised breast cancer screen-
ing in each region.
Despite the different effect sizes, we are confident that our three
regional estimates do not present an overestimation of the benefit of
mammographic screening. They are well in the range of an analysis of
Broeders et al from 20125 who present a pooled breast cancer mor-
tality reduction for women who actually participated in screening of
38% based on incidence based mortality studies [odds ratio (OR) = 0.62
(0.56-0.69)] and 48% based on case-control studies [OR = 0.52 (0.42-
0.65), adjusted for self-selection]. An analysis similar to our study has
been published in 2013. Mackenbach and McKee34 estimated there
would be over 17 000 fewer breast cancer deaths each year if all
countries in the EU could reduce death rates to those in the best per-
forming country, Sweden. However, our study was based on cause-
and age-specific death rates only rather than the combination of
cause- and age-specific mortality and the extent of screening activity.
To our knowledge, there have been no other studies so far that
have estimated the effect of breast cancer screening on cancer-specific
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mortality when brought to its full potential based on the total extent
of breast cancer screening activities in Europe. We were able to pro-
vide an extensive overview of the amount of organised as well as
opportunistic screening in Europe by consulting national experts.
Accordingly, some of the national estimates on screening uptake
have never been published before. However, our study also has some
potential limitations. The first limitation is the uncertainty regarding
the coverage of opportunistic screening as these numbers are based
on expert opinion or on national extrapolations of regional observa-
tions. Second, because the organised breast cancer screening in the
United Kingdom as well as Malta is triennially rather than every
2 years, this led to a slight overestimation of the breast cancer death
prevented. Third, our calculations probably led to an underestimation
of the already prevented and additionally preventable deaths for the
few countries which invite and screen women that are younger than
50 or older than 69. The fourth limitation is the fact that the number
of breast cancer deaths and the estimates of examination coverage
come from the same report year although the most recent breast
cancer deaths rather reflect the past (eg, 5-10 years ago) than current
screening practice.
Our analysis paves the way for further research as it could poten-
tially be applied to the other two cancer sites for which the European
Council recommends screening: cervical and colorectal cancer.
Our study illustrates that by further optimising screening cover-
age, the number of breast cancer deaths in Europe could be lowered
substantially. Therefore, countries which do not yet offer organised
screening for the target age range of 50 to 69 should strongly con-
sider it based on our results. In addition, even when programmes to
screen for breast cancer exist, much remains to be done. This includes
increasing screening coverage through evidence-based interven-
tions35,36 and removing barriers to effective breast cancer
screening.37,38
ACKNOWLEDGEMENTS
We like to thank all data providers and EU-TOPIA workshop partici-
pants for their valuable help, expert inputs and critical feedback in
the making of this study. This study is part of the EU-TOPIA project,
funded by the EU-Framework Programme (Horizon 2020) of the
European Commission, project reference 634753. The authors
alone are responsible for the views expressed in this manuscript.
CONFLICT OF INTEREST
H. J. d. K. reports personal fees from the University of Zurich/MSD.
All other authors of this paper report no conflicts of interest.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
ORCID
Nadine Zielonke https://orcid.org/0000-0001-6148-2371
Eveline A. M. Heijnsdijk https://orcid.org/0000-0002-4890-6069
Inge M. C. M. de Kok https://orcid.org/0000-0002-9419-0452
Harry J. de Koning https://orcid.org/0000-0003-4682-3646
REFERENCES
1. ECIS - European Cancer Information System: European Commission.
https://ecis.jrc.ec.europa.eu/. Accessed September 1, 2019.
2. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and
mortality patterns in Europe: estimates for 40 countries and 25 major
cancers in 2018. Eur J Cancer. 2018;103:356-387.
3. IARC. Cancer Screening in the European Union. Report on the Imple-
mentation of the Council Recommendation on Cancer Screening.
Lyon, France: IARC; 2017. 2017_cancerscreening_2ndreportimpleme
ntation_en.pdf.
4. Nelson HD, Fu R, Cantor A, Pappas M, Daeges M, Humphrey L.
Effectiveness of breast cancer screening: systematic review and
meta-analysisto update the 2009 U.S. Preventive Services Task Force
recommendation. Ann Intern Med. 2016;164(4):244-255.
5. Broeders M, Moss S, Nyström L, et al. The impact of mammographic
screening on breast cancer mortality in Europe: a review of observa-
tional studies. J Med Screen. 2012;19(suppl 1):14-25.
6. Moss SM, Nyström L, Jonsson H, et al. The impact of mammographic
screening on breast cancer mortality in Europe: a review of trend
studies. J Med Screen. 2012;19(suppl 1):26-32.
7. Zielonke N, Gini A, Jansen E, et al. Evidence for reducing cancer spe-
cific mortality due to screening for breast cancer in Europe: a system-
atic review. Eur J Cancer. 2020;127:191-206.
8. Weedon-Fekjræ H, Romundstad PR, Vatten LJ. Modern mammogra-
phy screening and breast cancer mortality: population study. BMJ.
2014;348:g3701.
9. Heinavaara S, Sarkeala T, Anttila A. Impact of organised mammogra-
phy screening on breast cancer mortality in a case-control and cohort
study. Br J Cancer. 2016;114:1038-1044.
10. Olsen AH, Lynge E, Njor SH, et al. Breast cancer mortality in Norway
after the introduction of mammography screening. Int J Cancer. 2013;
132(1):208-214.
11. Puliti D, Miccinesi G, Zappa M, Manneschi G, Crocetti E, Paci E.
Balancing harms and benefits of service mammography screening
programs: a cohort study. Breast Cancer Res. 2012;14(1):R9.
12. Paap E, Verbeek ALM, Botterweck AAM, et al. Breast cancer screen-
ing halves the risk of breast cancer death: a case-referent study.
Breast. 2014;23(4):439-444.
13. Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW.
Impact of screening on breast cancer mortality: the UK program
20 years on. Cancer Epidemiol Biomarkers Prev. 2016;25(3):455-462.
14. Johns LE, Coleman DA, Swerdlow AJ, Moss SM. Effect of population
breast screening on breast cancer mortality up to 2005 in England
and Wales: an individual-level cohort study. Br J Cancer. 2017;116(2):
246-252.
15. Tabár L, Vitak B, Chen THH, et al. Swedish two-county trial: impact
of mammographic screening on breast cancer mortality during 3
decades. Radiology. 2011;260(3):658-663.
16. Council of the European Union. Council recommendation of Decem-
ber 2, 2003 on cancer screening (2003/878/EC). OJ L. 2003;327:
34-38.
17. European Commission Initiative on Breast Cancer. Recommendations
from the European Breast Guidlines. 2020. https://ecibc.jrc.ec.
europa.eu/recommendations/. Accessed February 1, 2020.
18. Basu P, Ponti A, Anttila A, et al. Status of implementation and organi-
zation of cancer screening in the European Union Member States-
Summary results from the second European screening report. Int J
Cancer. 2018;142(1):44-56.
19. Chen TH, Yen AM, Fann JC, et al. Clarifying the debate on popula-
tion-based screening for breast cancer with mammography: a system-
atic review of randomized controlled trials on mammography with
ZIELONKE ET AL. 11
Bayesian meta-analysis and causal model. Medicine. 2017;96(3):
e5684.
20. Marmot MG, Altman DG, Cameron DA, et al. The benefits and harms
of breast cancer screening: an independent review. Br J Cancer. 2013;
108(11):2205-2240.
21. WHO. Cancer Mortality Database 2019. http://www-dep.iarc.fr/
WHOdb/WHOdb.htm. Accessed September 1, 2019.
22. The European Commission. ECIS - European Cancer Information
System. 2019. https://ecis.jrc.ec.europa.eu/. Accessed September 1,
2019.
23. IARC Working Group. IARC Handbooks of Cancer Prevention. Vol 15.
Lyon, France: Breast Cancer Screening; 2016.
24. Puliti D, Miccinesi G, Collina N, et al. Effectiveness of service screen-
ing: a case-control study to assess breast cancer mortality reduction.
Br J Cancer. 2008;99(3):423-427.
25. Bihrmann K, Jensen A, Olsen AH, et al. Performance of systematic
and non-systematic (‘opportunistic’) screening mammography: a com-
parative study from Denmark. J Med Screen. 2008;15(1):23-26.
26. Hofvind S, Vacek PM, Skelly J, Weaver DL, Geller BM. Comparing
screening mammography for early breast cancer detection in Ver-
mont and Norway. J Natl Cancer Inst. 2008;100(15):1082-1091.
27. Bulliard JL, Ducros C, Jemelin C, Arzel B, Fioretta G, Levi F. Effective-
ness of organised versus opportunistic mammography screening. Ann
Oncol. 2009;20(7):1199-1202.
28. Espinas JA, Aliste L, Fernandez E, et al. Narrowing the equity gap: the
impact of organized versus opportunistic cancer screening in Catalo-
nia (Spain). J Med Screen. 2011;18(2):87-90.
29. de Gelder R, Bulliard JL, de Wolf C, et al. Cost-effectiveness of oppor-
tunistic versus organised mammography screening in Switzerland. Eur
J Cancer. 2009;45(1):127-138.
30. Perry N, Broeders M, de Wolf C, Törnberg S, Holland R, von Karsa L.
European guidelines for quality assurance in breast cancer screening
and diagnosis. Fourth edition—summary document. Ann Oncol. 2008;
19(4):614-622.
31. van Agt H, Fracheboud J, van der Steen A, de Koning H. Do women
make an informed choice about participating in breast cancer screen-
ing? A survey among women invited for a first mammography screen-
ing examination. Patient Educ Couns. 2012;89(2):353-359.
32. Autier P, Boniol M. Breast cancer screening: evidence of benefit
depends on the method used. BMC Med. 2012;10:163.
33. Lauby-Secretan B, Scoccianti C, Loomis D, et al. Breast-cancer
screening—viewpoint of the IARC Working Group. N Engl J Med.
2015;372(24):2353-2358.
34. Mackenbach JP, Karanikolos M, McKee M. The unequal health of
Europeans: successes and failures of policies. Lancet. 2013;381
(9872):1125-1134.
35. Jepson R, Clegg A, Forbes C, et al. The determinants of screening
uptake and interventions for increasing uptake: a systematic review.
Health Technol Assess. 2000;4(14):i-vii.
36. Camilloni L, Ferroni E, Cendales BJ, et al. Methods to increase partici-
pation in organised screening programs: a systematic review. BMC
Public Health. 2013;13:464.
37. Turnbull E, Priaulx J, van Ravesteyn NT, et al. A health systems
approach to identifying barriers to breast cancer screening
programmes. Methodology and application in six European countries.
Health Policy. 2018;122(11):1198-1205.
38. Priaulx J, de Koning HJ, de Kok I, et al. Identifying the barriers to
effective breast, cervical and colorectal cancer screening in thirty one
European countries using the Barriers to Effective Screening Tool
(BEST). Health Policy. 2018;122(11):1190-1197.
How to cite this article: Zielonke N, Kregting LM,
Heijnsdijk EAM, et al. The potential of breast cancer screening
in Europe. Int. J. Cancer. 2020;1–13. https://doi.org/10.1002/
ijc.33204
12 ZIELONKE ET AL.
APPENDIX: EU-TOPIA COLLABORATORS
TABLE A1 EU-TOPIA collaborators
Austria Gerald Gredinger1
Belgium (national) Cancer registry (I. De Brabander1), Sciensano (M. Arbyn,1 C. Simoens1)
Belgium—Flanders P. Martens1
Belgium—Wallonia Michel Candeur1
Belgium—Brussel Marc Arbyn1, Cindy Simoens1, JB. Burrion1
Bulgaria Plamen Dimitrov1, Zdravka Valerianova1
Croatia Andrea Supe1
Czech Republic Ondřej Ngo1, Ondřej Májek1
Denmark Elisabeth Lynge1
Estonia Piret Veerus2
Finland Sirpa Heinävaara2, Ahti Anttila, Tytti Sarkeala
France Agnes Rogel1
Germany Vanessa Kääb-Sanyal1, Klaus Kraywinkel1
Hungary Marcell Csanadi2, György Széles, Zoltan Voko







The Netherlands Linda de Munck1, Inge de Kok, Andrea Gini, Eveline Heijnsdijk, Erik Jansen,
Harry de Koning, Iris Lansdorp – Vogelaar, Nicolien van Ravesteyn
Norway Solveig Hofvind1
Poland Anna Macios1
Spain Nieves Ascunce Elizaga1
Slovakia Soňa Senderáková1
Slovenia Katja Jarm2, Urska Ivanus, Dominika Novak Mlakar
Sweden Lennarth Nyström1
Switzerland Jean-Luc Bulliard1
United Kingdom—Scotland John Quinn1
United Kingdom—Northern Ireland Jeni Rosborough1
United Kingdom—Wales Ardiana Gjini1
United Kingdom—England Radoslav Latinovic1, Martin McKee
1Data providers.
2EU-TOPIA consortium members (or both).
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